EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024

An overview of the science behind DURAVYU™ (vorolanib intravitreal insert), formerly known as EYP1901, an investigational sustained-release therapy with the potential to alter the treatment paradigm for patients suffering from VEGF-mediated retinal diseases A review of the positive Phase 2 DAVIO 2 trial results in wet AMD, including 12-month topline data An update on the pivotal non-inferiority Phase 3 trial plans for DURAVYU™ in wet AMD A KOL roundtable discussion with Drs. Regillo and Modi moderated by Ey ...